Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$50.94 USD
+0.93 (1.86%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $50.94 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BMY 50.94 +0.93(1.86%)
Will BMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
Other News for BMY
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Geron: Derisked And Highly Attractive After Approval
UCB gets expanded FDA approval for psoriasis drug Bimzelx
Raise Cash And Sell Trash
Sanofi Sarclisa combo gains approval as first-line multiple myeloma treatment